Abstract Neurodegenerative disorders, including Alzheimer's (AD) and Parkinson's diseases (PD), are characterised by the formation of aberrant assemblies of misfolded proteins. The discovery of disease-modifying drugs for these disorders is challenging, in part because we still have a limited understanding of their molecular origins. In this review, we discuss how biophysical approaches can help explain the formation of the aberrant conformational states of proteins whose neurotoxic effects underlie these diseases. We discuss in particular models based on the transgenic expression of amyloid-β (Aβ) and tau in AD, and α-synuclein in PD. Because biophysical methods have enabled an accurate quantification and a detailed understanding of the molecular mechanisms underlying protein misfolding and aggregation in vitro, we expect that the further development of these methods to probe directly the corresponding mechanisms in vivo will open effective routes for diagnostic and therapeutic interventions.
Introduction: The Resolution Gap in Neurodegeneration
The hallmark of neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD) is the aggregation of specific proteins—namely amyloid-β (Aβ), tau, and α-synuclein. Despite decades of research, the development of disease-modifying therapies remains elusive. A primary obstacle is the "resolution gap" between different experimental scales. In vitro studies offer high-resolution molecular details but lack biological complexity, while in vivo animal models demonstrate pathology and symptoms but often obscure the specific molecular species responsible for neurotoxicity.
This review synthesizes research aimed at bridging this gap by applying biophysical rigor to living systems. The goal is to identify which microscopic aggregation steps—such as primary nucleation or fibril fragmentation—drive disease progression in the brain.
Quantifying Aggregation: A Kinetic Approach
To understand how proteins misfold in a living organism, researchers employ chemical kinetics to decompose the aggregation process into distinct microscopic steps. These include:
- Primary Nucleation: The initial formation of small aggregates from soluble monomers.
- Elongation: The growth of existing fibrils through the addition of monomers.
- Secondary Nucleation: The surface-catalyzed formation of new aggregates on the exterior of existing fibrils.
- Fragmentation: The breaking of fibrils into smaller pieces, which then act as new seeds for growth.
By measuring the rate of these processes (as seen in the sigmoidal curves of fibrillar mass concentration over time in the figure above), biophysicists can pinpoint the specific pathways that lead to an exponential increase in toxic species.
Key Insights: The Role of Toxic Oligomers
A central finding in recent biophysical studies is that large, visible protein "plaques" or "tangles" may be relatively inert. Instead, the most neurotoxic species are likely small, transient, and soluble oligomers formed during intermediate stages of aggregation.
For Aβ42, the variant most closely associated with Alzheimer’s, the surface of existing fibrils acts as a potent catalyst for secondary nucleation. This creates a positive feedback loop, leading to an explosion of toxic oligomers that likely overwhelms cellular quality control systems. This mechanism explains why Aβ42 is significantly more pathogenic than Aβ40, which lacks such robust secondary nucleation rates.
Experimental Models and Advanced Imaging
The review highlights a hierarchy of models and techniques used to study these phenomena:
- Simple Transgenic Models: Organisms like C. elegans (worms) and Drosophila (flies) allow for high-throughput genetic screens. There is a striking correlation between the in vitro aggregation rates of protein mutants and the reduction in lifespan or locomotion in these models, suggesting that basic biophysical properties directly dictate disease severity.
- Complex Rodent Models: These are essential for recapitulating human brain anatomy and complex behavioral phenotypes.
- Advanced Imaging and Structural Resolution: Techniques such as Fluorescence Lifetime Imaging Microscopy (FLIM) and smFRET detect protein conformational changes in situ. Furthermore, recent advances in Cryo-EM have allowed researchers to resolve the atomic structure of fibrils extracted directly from human patient brains, revealing that in vivo aggregates can differ significantly from those grown in a lab.
Future Perspectives and Challenges
While progress has been significant, several challenges remain. Most in vivo studies are currently "endpoint" analyses, requiring the sacrifice of the animal. There is a critical need for non-invasive, longitudinal tools—such as improved PET tracers or MRI techniques—to monitor aggregation in real-time within a single subject.
Furthermore, most current models rely on rare genetic mutations to drive aggregation. Future research must shift toward "wild-type" protein aggregation to better reflect the sporadic, late-onset cases that constitute the majority of human neurodegenerative disease. By refining our ability to detect "invisible" transient oligomers and understanding the role of Liquid-Liquid Phase Separation (LLPS) in early aggregation, we may finally unlock effective therapeutic interventions.
Summary updated